Ingevity Corp Files 8-K on Financials
Ticker: NGVT · Form: 8-K · Filed: 2024-05-01T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, results-of-operations
Related Tickers: NGVT
TL;DR
Ingevity dropped an 8-K detailing their financial results - check it out!
AI Summary
Ingevity Corporation filed an 8-K on May 1, 2024, reporting on its financial condition and results of operations. The filing includes financial statements and exhibits related to the company's performance.
Why It Matters
This 8-K filing provides investors with crucial updates on Ingevity's financial performance and condition, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Ingevity Corporation (company) — Registrant
- May 1, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 4920 O'Hear Avenue Suite 400 North Charleston South Carolina 29405 (address) — Principal Executive Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Ingevity Corporation's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on May 1, 2024.
In which state is Ingevity Corporation incorporated?
Ingevity Corporation is incorporated in Delaware.
What is the principal business address of Ingevity Corporation?
The principal business address of Ingevity Corporation is 4920 O'Hear Avenue, Suite 400, North Charleston, South Carolina 29405.
What is the SIC code for Ingevity Corporation?
The Standard Industrial Classification (SIC) code for Ingevity Corporation is 2800, which falls under CHEMICALS & ALLIED PRODUCTS.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-05-01 16:19:14
Key Financial Figures
- $0.01 — ange on which registered Common Stock ($0.01 par value) NGVT New York Stock Exchange
Filing Documents
- ngvt-20240501.htm (8-K) — 28KB
- ex99103312024.htm (EX-99.1) — 320KB
- image1.jpg (GRAPHIC) — 143KB
- ngvt-20240501_g1.jpg (GRAPHIC) — 143KB
- 0001653477-24-000055.txt ( ) — 987KB
- ngvt-20240501.xsd (EX-101.SCH) — 2KB
- ngvt-20240501_lab.xml (EX-101.LAB) — 21KB
- ngvt-20240501_pre.xml (EX-101.PRE) — 12KB
- ngvt-20240501_htm.xml (XML) — 3KB
02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION On May 1, 2024 , Ingevity Corporation ("Ingevity") announced its preliminary financial results for the three months ended March 31, 2024 which are attached as Exhibit 99.1 to this Current Report on Form 8-K. Please refer to our website for additional information regarding Ingevity. Periodically we may provide other information on the investor relations page of our website. Interested parties are encouraged to visit Ingevity's website to view such other information including Ingevity slide presentations. The information contained in Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press release dated May 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INGEVITY CORPORATION (Registrant) By: /S/ MARY DEAN HALL Mary Dean Hall Executive Vice President and Chief Financial Officer Date: May 1, 2024